Your browser doesn't support javascript.
loading
Enhancing Inactivated Yellow Fever 17D Vaccine-Induced Immune Responses in Balb/C Mice Using Alum/CpG.
Zhang, Yadan; Yang, Rong; Yuan, Guangying; Li, Weidong; Cui, Zihao; Xiao, Zhuangzhuang; Dong, Xiaofei; Yang, Hongqiang; Liu, Xiaojuan; Zhang, Le; Hou, Yirong; Liu, Manyu; Liu, Sushi; Hao, Yu; Zhang, Yuntao; Zheng, Xiaotong.
Afiliação
  • Zhang Y; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Yang R; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Yuan G; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Li W; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Cui Z; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Xiao Z; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Dong X; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Yang H; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Liu X; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Zhang L; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Hou Y; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Liu M; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Liu S; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Hao Y; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Zhang Y; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
  • Zheng X; Beijing Institute of Biological Products Company Limited, Beijing 100170, China.
Vaccines (Basel) ; 11(12)2023 Nov 22.
Article em En | MEDLINE | ID: mdl-38140149
ABSTRACT
There are some concerns about the safety of live attenuated yellow fever vaccines (YF-live), particularly viscerotropic adverse events, which have a high mortality rate. The cellular production of the vaccine will not cause these adverse effects and has the potential to extend applicability to those who have allergic reactions, immunosuppression, and age. In this study, inactivated yellow fever (YF) was prepared and adsorbed with Alum/CpG. The cellular and humoral immunities were investigated in a mouse model. The results showed that Alum/CpG (20 µg/mL) could significantly increase the binding and neutralizing activities of the antibodies against YF. Moreover, the antibody level at day 28 after one dose was similar to that of the attenuated vaccine, but significantly higher after two doses. At the same time, Alum/CpG significantly increased the levels of IFN-γ and IL-4 cytokines.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Vaccines (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China País de publicação: Suíça